TY  - JOUR 
AU  - Vázquez Estévez, Sergio
PY  - 2012
SN  - 0959-4973
UR  - http://hdl.handle.net/20.500.11940/493
LA  - eng
TI  - Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2
DO  - http://dx.doi.org/10.1097/CAD.0b...
T2  - ANTI-CANCER DRUGS
VL  - 23
ER  -